Skip to main content

Assessment of the appropriate cutoff points for anthropometric indices and their relationship with cardio-metabolic indices to predict the risk of metabolic associated fatty liver disease

Abstract

Background

Research on Metabolic Associated Fatty Liver Disease (MAFLD) is still in its early stages, with few studies available to identify and predict effective indicators of this disease. On the other hand, early diagnosis and intervention are crucial to reduce the burden of MAFLD. Therefore, the aim of this research was to investigate the effectiveness of eleven anthropometric indices and their appropriate cut-off values as a non-invasive method to predict and diagnose MAFLD in the Iranian population.

Methods

In this cross-sectional study, we analyzed baseline data from the Hoveyzeh Cohort Study, a prospective population-based study conducted in Iran that enrolled a total of 7836 subjects aged 35 to 70 years from May 2016 through August 2018.

Results

The optimal cut-off values of anthropometric indices for predicting MAFLD risk were determined for waist circumference(WC) (102.25 cm for males and 101.45 cm for females), body mass index (BMI) (27.80 kg/m2 for males and 28.75 kg/m2 for females), waist-to-hip ratio (WHR) (0.96 for both males and females), waist-to-height ratio (WHtR) (0.56 for males and 0.63 for females), body adiposity index (BAI) (23.24 for males and 32.97 for females), visceral adiposity index (VAI) (1.64 for males and 1.88 for females), weight-adjusted waist index (WWI) (10.63 for males and 11.71 for females), conicity index (CI) (1.29 for males and 1.36 for females), body roundness index (BRI) (4.52 for males and 6.45 for females), relative fat mass (RFM) (28.18 for males and 44.91 for females) and abdominal volume index (AVI) (18.85 for males and for 21.37 females). VAI in males (sensitivity: 77%, specificity: 60%, Youden’s Index: 0.37) and RFM in females (sensitivity: 76%, specificity: 59%, Youden’s Index: 0.35) were found to have higher sensitivity and specificity compared to other anthropometric indices. Furthermore, anthropometric indices demonstrated statistically significant correlations with various hepatic and cardiometabolic indices. Among these, the strongest positive correlations were observed between WC, BMI, BAI, BRI, and AVI with the Hepatic Steatosis Index (HSI), TyG-BMI, and TyG-WC, as well as between VAI and the Atherogenic Index of Plasma (AIP), Lipid Accumulation Product (LAP), Cardiometabolic Index (CMI), and the Triglyceride and Glucose (TyG) Index.

Conclusion

Anthropometric indices are effective in predicting MAFLD risk among Iranian adults, with WWI, VAI, and RFM identified as the strongest predictors. The proposed cutoff values could serve as a straightforward and non-invasive methods for the early diagnosis of MAFLD.

Peer Review reports

Introduction

A group of international experts from 22 countries proposed a new concept for fatty liver disease in 2020, which is called metabolic (dysfunction) associated with fatty liver disease (MAFLD) [1]. As a result, the condition previously known as non-alcoholic fatty liver disease (NAFLD) has been renamed to MAFLD, which enables the identification of a larger number of individuals with fatty liver [2].

Additionally, the transition from NAFLD to MAFLD has been endorsed by several organizations, including the European Liver Patients’ Association [3]. MAFLD is defined as a condition characterized by hepatic steatosis, as well as the presence of at least one metabolic dysfunction, including overweight or obesity (body mass index ≥ 25 kg/m2), arterial hypertension, diabetes, cardiovascular diseases (CVD), and dyslipidemia [4,5,6].

Approximately 25% of the global adult population is affected by MAFLD, imposing significant burdens on individuals, economies, and healthcare systems [6, 7]. The underlying mechanisms and processes that contribute to the development and progression of MAFLD are still not well understood. Genetic variation, type 2 diabetes mellitus (T2DM), insulin resistance (IR), dyslipidemia, and cardiovascular disease (CVD) are all examples of associative factors [8].

Furthermore, the increasing prevalence of MAFLD is linked to the rising prevalence of obesity [9]. According to a recent systematic review and meta-analysis, it was found that MAFLD prevalence among overweight or obese adults in the general population was 50.7% [10]. Several studies have also found strong associations between MAFLD and anthropometric measurements, such as body mass index (BMI), waist circumference (WC), and waist-to-height ratio (WHtR) [11, 12].

Obesity has a significant impact on the liver due to the presence of adipokines, which are hormones produced by adipose tissue. Adipokines play critical roles in the development of various stages of MAFLD, including steatosis, nonalcoholic steatohepatitis (NASH), cirrhosis, and carcinogenesis [13].

The high prevalence of cardiometabolic diseases worldwide, which are closely linked to obesity, makes cardiometabolic health a significant public health issue [14, 15]. In addition, there is ample evidence of clear associations between NAFLD and various cardiometabolic disorders, such as ischemic stroke, insulin resistance, hypertension, cardiac arrhythmias, and dyslipidemia [16, 17]. A study showed that MAFLD criteria are more effective than those for NAFLD in identifying individuals at elevated risk for cardiovascular disease [1]. Furthermore, based on the study by Kim et al. [18], MAFLD is associated with a higher risk of cardiovascular mortality.

Although MAFLD is highly prevalent worldwide, there are currently no approved treatments available for this condition [12]. Early diagnosis and assessment of the associated risk factors would greatly aid in the prevention or management of MAFLD. Therefore, this study was conducted to assess the predictive ability of anthropometric indices and determine their optimal cutoff values for predicting MAFLD risk in the Iranian population.

Materials and methods

Patients and study design

The cross-sectional study was part of the Hoveyzeh Cohort Study, a prospective population-based study of noncommunicable diseases in an Arab community in southwestern Iran. This study targeted adults aged 35 to 70 years, from May 2016 through August 2018 [19]. According to Fig. 1, among the respondents (n = 10,009) in the city of Hoveyzeh, 7836 individuals were evaluated using inclusion and exclusion criteria. Inclusion criteria included willingness to participate in the study and being between 35 and 70 years old. Exclusion criteria included pregnancy, lactation, and alcohol consumption.Finally, after excluding subjects with incomplete or illogical data related to anthropometric and cardiometabolic indices, 7836 participants, comprising 3190 males and 4646 females, were eligible for the study. Out of these, 642 were diagnosed with MAFLD as NAFLD patients with at least one of the following three conditions: obesity, type 2 diabetes mellitus, and metabolic dysregulation.

Fig. 1
figure 1

Flow diagram of study selection

Data collection

All data related to this study were recorded in the Hoveyzeh Cohort Study database and extracted for this research.

Anthropometric indices

The anthropometric assessment included measurements of weight, height, WC, wrist, hip circumference (HC), BMI, WHR, WHtR, BAI, VAI, WWI, CI, BRI, RFM, and AVI were calculated.

Body weight (in kg) was measured using a standing scale (Seca 755), and height (in cm) was measured with a stadiometer (Seca 206). WC, wrist circumference (in cm), and HC were measured using Seca locked tape meters. All measurements were performed by trained nursing staff using standard protocols and techniques.Anthropometric indicators were calculated using the following standard equations:

$$\mathrm{BMI}\hspace{0.17em}=\hspace{0.17em}\mathrm{weight}\left(\mathrm{kg}\right)/\mathrm{height}\left(\mathrm m\right)^2$$
$$\mathrm{WHR}\hspace{0.17em}=\hspace{0.17em}\mathrm{WC}\left(\mathrm{cm}\right)/\mathrm{HC}\left(\mathrm{cm}\right)$$
$$\mathrm{WHtR}\hspace{0.17em}=\hspace{0.17em}\mathrm{WC}\left(\mathrm{cm}\right)/\mathrm{height}\left(\mathrm{cm}\right)$$
$$\mathrm{BAI}=\lbrack\mathrm{HC}(\mathrm{cm})/\mathrm{height}(\mathrm m)^{1.5}\rbrack-18$$
$$\mathrm{ABSI}=\mathrm{WC (m)} / \mathrm{[{BMI}^{2/3}(kg/m^{2}) height^{1/2} (m)]}$$
$$\mathrm{VAI}\,=\,(\mathrm{WC}\,(\mathrm{cm})\,/\,\lbrack39.68\,+\,(1.88\,\times\,\mathrm{BMI})\rbrack\,\times\,(\mathrm{TG}\,(\mathrm{mmol}/\mathrm L)/1.03)\,\times\,(1.31/\,\mathrm{HDL}\,(\mathrm{mmol}/\mathrm L))\,\mathrm{in}\,\mathrm{males}$$
$$\mathrm{VAI}\,=\,(\mathrm{WC}\,(\mathrm{cm})\,/\,\lbrack36.58\,+\,(1.89\,\times\,\mathrm{BMI})\rbrack\,\times\,(\mathrm{TG}\,(\mathrm{mmol}/\mathrm L)/0.81)\,\times\,(1.52/\,\mathrm{HDL}\,(\mathrm{mmol}/\mathrm L))\,\mathrm{in}\,\mathrm{females}$$
$$\mathrm{WWI}\hspace{0.17em}=\hspace{0.17em}\mathrm{WC}\left(\mathrm{cm}\right)/\mathrm{Weight}\left(\mathrm{kg}\right)^2$$
$$\mathrm{CI}\hspace{0.17em}=\hspace{0.17em}\mathrm{WC}\left(\mathrm m\right)/\lbrack0.109\times\sqrt{\mathrm{weight}\left(\mathrm{kg}\right)/\mathrm{Height}\left(\mathrm m\right)}\rbrack$$
$$BRI=364.2-365.5\times(1-[\mathrm{WC}/2\pi]^2/[0.5\times\mathrm{height}^2)^{\frac{1}{2}}$$
$$RFM\hspace{0.17em}=\hspace{0.17em}64 - (20 \times height/WC (cm\left)\right) + (12 \times sex); sex\hspace{0.17em}=\hspace{0.17em}0\, for\, males\, and\, 1\,for\,females$$
$$\mathrm{AVI}=\lbrack2\times\mathrm{WC}\left(\mathrm{cm}\right)^2+0.7\times(\mathrm{WC}\left(\mathrm{cm}\right)-\mathrm{HC}{\left(\mathrm{cm}\right))}^2\rbrack/1000$$

Biochemical test and blood pressure measurement

Venous blood (10 ml) was taken from all patients after a 12-hour overnight fasting period.The blood samples were centrifuged, and the serums were stored at -70 ° C. A complete blood count (CBC) was performed using the hematology autoanalyser (Nihon Kohden 6510-k, Japan). Serum glucose, triglyceride (TG), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-C) levels were assessed using a commercial kit (Pars Azmoon, Tehran, Iran). Serum low-density lipoprotein cholesterol (LDL) was calculated using the Friedewald equation.

Brachial blood pressure (BP) was measured in the supine position after at least 10 min of rest. Triple brachial blood pressure recording was performed on the right arm using a validated automated oscillometric device.

Mean Arterial Pressure \(\left(MAP\right) = [Systolic BP + (2 \times Diastolic BP\left)\right]/3\)  

Cardiometabolic and hepatic indices

Cardiometabolic indices were calculated using the following formulas:

The atherogenic index of plasma \(\left(AIP\right)\hspace{0.17em}=\hspace{0.17em}Log (TG/ HDL-C)\)

lipid accumulation product \(\left(LAP\right) = \left[WC \right(cm)-65] \times \left[TG\right] in males, \left[WC \right(cm)-58] \times \left[TG\right]\) in females

Lipoprotein combine index \(\left(LCI\right)\hspace{0.17em}=\hspace{0.17em}TC\times TG\times LDL/HDL-C\)

Cardiometabolic index \(\left(CMI\right)\hspace{0.17em}=\hspace{0.17em}TG/HDL-C \times WHtR\)

$$TyG\ index: Ln \left[TG \right(mg/dl) \times FPG (mg/dl)/2]$$
$$TyG-BMI: TyG index \times BMI$$
$$TyG-WC: TyG index \times waist circumference \left(cm\right)$$

Thrombolysis in Myocardial Infarction \(\left(TIMI risk index\right) score\hspace{0.17em}=\hspace{0.17em}heart rate \left(bpm\right) \times (age/{10)}^{2} /systolic BP (mmHg)\)

Cardiovascular risk index \(\left(CRI\right)\hspace{0.17em}=\hspace{0.17em}TC/HDL-C\)

Atherogenic index \(\left(AI\right)\hspace{0.17em}=\hspace{0.17em}LDL-C/HDL-C\)

Hepatic indices were calculated using the following formulas:

Hepatic steatosis index \(\left(HSI\right)\hspace{0.17em}=\hspace{0.17em}8 \times (ALT/AST ratio)\hspace{0.17em}+\hspace{0.17em}BMI (+\hspace{0.17em}2, if female; + 2, if diabetes mellitus)\).

$$ALD / NAFLD Index \left(ANI\right) = -58.5\hspace{0.17em}+\hspace{0.17em}0.637 \left(MCV\right)\hspace{0.17em}+\hspace{0.17em}3.91 (AST/ALT)-0.406 \left(BMI\right)\hspace{0.17em}+\hspace{0.17em}6.35$$

Aspartate aminotransferase-to-alanine aminotransferase ratio \(\left(AAR\right)\hspace{0.17em}=\hspace{0.17em}AST/ ALT\)

Statistical analysis

Statistical analysis was conducted using IBM SPSS Statistics software (Version 24). The Kolmogorov-Smirnov test was used to assess the normality of the variables. Means and standard deviations (SD) were used to describe continuous variables, while numbers and percentages (%) were used to describe categorical variables. The t-test and the Mann-Whitney U test (for non-normal distributed variables) were used to compare continuous variables. The Chi-squared test was used to compare the categorical variables. Pearson’s correlation coefficient was used because of the observed linear correlation between mean anthropometric indices and hepatic and cardio-metabolic indices. Linear regression analysis was used in three models: Model 1: unadjusted; Model 2: adjusted for age and energy intake), and Model 3: adjusted for age, dietary intake (energy, fat, protein, and carbohydrate), and wrist circumference to determine the association between anthropometric indices and MAFLD. A p-value of less than 0.05 was considered statistically significant.

Results

The study included 3190 males (40.7%) and 4646 females (59.2%). Among them, 212 males (33.0%) and 430 females (66.9%) were diagnosed with MAFLD. Table 1 presents a comparison of the population characteristics between individuals with and without MAFLD, categorized by gender (males and females). In both groups (MAFDL and non-MAFLD), the mean values for weight, height, wrist, systolic blood pressure, diastolic blood pressure, triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), and hemoglobin were significantly higher in males than in females. The mean values of BMI, WC, HC, heart rate, and HDL were also significantly higher in females than in males.

Table 1 Characteristics of the study population (n = 7836)

Patients with MAFLD showed significant differences compared to non-MAFLD individuals, particularly in anthropometric indices such as weight, height, BMI, wrist, WC and HC in both sexes (Table 1). Moreover, in all patients with MAFLD, age, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, triglycerides (TG), fasting blood sugar (FBS), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), were significantly higher compared to those without MAFLD. HDL levels were significantly lower in patients with MAFLD, whereas total cholesterol (TC), low-density lipoprotein (LDL), and aspartate transaminase (AST) levels showed no significant differences between the two groups.

Pearson’s correlation coefficients of anthropometric indices with hepatic and cardio-metabolic indices in MAFLD patients are summarized in Table 2. Anthropometric indices demonstrated statistically significant correlations with several variables, except for the pairs “CMI/RFM”, “TyG index/RFM”, “TIMI risk index/VAI”, and “AI/WWI”. Among the observed correlations, the strongest positive ones were between WC/BMI/BAI/BRI/AVI and HIS/TyG-BMI/TyG-WC, as well as VAI and AIP/LAP/CMI/TyG Index.On the other hand, WHtR exhibited the strongest negative correlation with HIS, TyG-BMI, and TyG-WC.

Table 2 Pearson’s correlation coefficients between anthropometric indices and hepatic and cardio-metabolic indices among males and females

The logistic regression analysis revealed that all anthropometric indices were significantly associated with MAFLD (P < 0.001) even after ajusting for potential confounding variables. However, WWI had the strongest association with MAFLD in males [ORs 1.747 (95% CI, 1.402–1.178)] and females [ORs 1.743 (95% CI, 1.506–2.018)]. After adjusting for potential confounding variables such as age and energy intake in Model 2, and also for age, dietary intake (energy, fat, protein, and carbohydrate), and wrist circumference in Model 3, the OR (95% CI) for WWI demonstrated a significant increase (P < 0.001) (Table 3).

Table 3 Logistic regression analyses for investigation of the association between anthropometric indices and MAFLD

Table 4 displays the adjusted ORs of MAFLD risk conditions with one SD increase in anthropometric indices. Odds ratios were adjusted for age, dietary intake (energy, fat, protein and carbohydrate) and wrist circumference. All anthropometric indices were significantly associated with MAFLD risk factors except VAI (OR = 1.02, 95% CI: 0.97–1.07; p = 0.472) and CI (OR = 1.02, 95% CI: 1.00-1.04; p = 0.069) for male hypertension and CI (OR = 1.01, 95% CI: 1.00-1.03; p = 0.232) for female hypertension. Also, our analysis identified VAI as a powerful predictor for MAFLD risk factors, demonstrating a particularly strong association with the presence of at least one risk factor in both males (OR = 11.79, 95% CI: 9.57–14.51) and females (OR = 6.57, 95% CI: 5.87–7.76).Similarly, WWI showed a significant correlation with MAFLD risk factors, notably diabetes in both males(OR = 3.81, 95% CI: 2.40–6.04) and females (OR = 2.28, 95% CI: 1.73–3.01). Conversely, WHtR demonstrated a notably weaker association with MAFLD risk factors, particularly diabetes in both males(OR = 0.007, 95% CI: 0.01–0.051) and females (OR = 0.02, 95% CI: 0.01–0.08).

Table 4 Odd ratios and 95% CI for MAFLD risk conditions corresponding to one SD increase in anthropometric indices

Estimated gender-specific optimal cut-off values for predicting MAFLD risk were used as binary classifiers for establishing the new cut-off points for the anthropometric indicators. The optimal cut-off values of anthropometric indices for predicting MAFLD risk were determined for WC (102.25 cm for males and 101.45 cm for females), BMI (27.80 kg/m2 for males and 28.75 kg/m2 for females), WHR (0.96 for both males and females), WHtR (0.56 for males and 0.63 for females), BAI (23.24 for males and 32.97 for females), VAI (1.64 for males and 1.88 for females), WWI (10.63 for males and 11.71 for females), CI (1.29 for males and 1.36 for females), BRI (4.52 for males and 6.45 for females), RFM (28.18 for males and 44.91 for females) and AVI (18.85 for males and for 21.37 females). VAI in males (sen:77%, spe:60%, YI; 0.37) and RFM in female (sen:76%, spe:59%, YI; 0.35) had the highest sensitivity and specificity than other anthropometric indices (Table 5). The ROC curve for the investigated indicators shown in Figs. 2 and 3.

Table 5 Optimal cut-off value for anthropometric indices predictive of MAFLD
Fig. 2
figure 2

The area under the curve (AUC) for (A) WC in male, (B) WC in female, (C) BMI in male, (D) BMI in female, (E) WHR in male, (F) WHR in female, (G) WHtR in male, (H) WHtR in female, (I) BAI in male, (J) BAI in female, K. VAI in male, L. VAI in female

Fig. 3
figure 3

The area under the curve (AUC) for (A) WWI in male, (B) WWI in female, (C) CI in male, (D) CI in female, (E) BRI in male, (F) BRI in female, (G) RFM in male, (H) RFM in female, (I) AVI in male, (J) AVI in female

Discussion

This cross-sectional study demonstrated that anthropometric indices are significant in predicting Metabolic Associated Fatty Liver Disease (MAFLD).The precise causes and factors contributing to the development and severity of MAFLD are still not well understood. Given the high prevalence rate of MAFLD worldwide, early diagnosis and intervention are essential to alleviate the burden of this disease. The occurrence and progression of fatty liver are significantly influenced by metabolic disorders, nutrition, and lifestyle [20]. The presence of cardiovascular disease along with certain anthropometric indices like body mass index (BMI), waist circumference (WC), and waist-to-height ratio (WHtR) may be effective in predicting MAFLD risk [11].

In this cross-sectional study, various anthropometric indices were measured, including WC, BMI, WHR, WHtR, BAI, VAI, WWI, CI, BRI, RFM, and AVI. In our study, logistic regression analysis assessed the association between these indices and MAFLD. The results revealed that WWI had the highest odds ratios in males and females, both before and after adjusting for confounding factors. In 2018, the weight-adjusted waist index (WWI) was initially proposed as a measurement of central obesity that considers both fat and muscle mass components, independent of the body mass index [21]. Multiple studies have demonstrated a notable correlation between WWI and various health conditions such as cardiovascular disease, chronic kidney disease, hepatic steatosis, and hepatic fibrosis [21, 22].

Our study revealed a strong positive correlation between WC, BMI, BAI, BRI and AVI with HIS, TyG-BMI and TyG-WC, as well as between VAI with AIP, LAP, CMI and TyG Index, as indicated by Pearson’s correlation coefficients. However, some studies have shown that LAP is the best predictor of obese individuals with MAFLD, with the maximum ORs value [11, 23]. Also, In a cross-sectional study that included 7968 participants, Yang et al. [24] discovered that TyG-BMI, BMI, TyG, TG/HDL-C, and TG are five significant predictors of the risk of MAFLD.

The highest odds ratios were found for VAI in relation to dyslipidemia and having one or more risk factors for MAFLD. In addition, the cut-off values for anthropometric indices used to predict MAFLD, varied by gender. According to our results, VAI in males and RFM in females had the highest sensitivity and specificity in predicting MAFLD risk, with the cut-off values of 1.64 and 44.91, respectively. The visceral adiposity index (VAI) has been suggested as a reliable indicator for the accumulation and dysfunction of visceral fat, and it has been demonstrated to have a strong correlation with the presence of type 2 diabetes, cardiovascular events, and hepatic fibrosis [25]. Recently, Ismaiel et al. [26] in a meta-analysis study, demonstrated that the VAI has a predictive value for diagnosing NAFLD and NASH, with noticeably higher values observed in adult patients with NAFLD.

The authors of a study suggested that a higher risk of developing NAFLD over a 4-year period is associated with larger areas of visceral adipose tissue, and that the distribution of fat has a greater impact on NAFLD than the content of the fat. This mechanism explains the relationship between VAI and NAFLD [26]. Additionally, the relative fat mass (RFM) is a basic linear equation that relies on the ratio of height to waist circumference [27]. One study has demonstrated that obesity defined by RFM is more effective in predicting dyslipidemia, hypertension, and abnormal secretion of adipokines. However, it does not offer additional benefits in predicting non-alcoholic fatty liver disease (NAFLD) or liver damage compared to obesity defined by BMI [28].

For both sexes, the optimal cut-off values for BMI were lower (27.80 kg/m2 in males, 28.75 kg/m2 in female) than the values indicating obesity (> 30 kg/m2). The BMI cutoff points obtained by Jing Liu et al. [23], Cai et al. [11], and Yang et al. [24] were 25.39, 24, and 24.61 kg/m2 respectively, which were lower than our findings. It is well accepted that BMI is closely related to the risk of fatty liver disease and is an important factor in determining negative clinical outcomes [10]. On the contrary, Jing Liu et al. [23] suggested that BMI is not a valuable diagnostic indicator for MAFLD. Nevertheless, the correlation between MAFLD and BMI is intricate and can be affected by numerous factors, including one’s racial or ethnic background and variations in specific genes [10].

Furthermore, in the present study, the optimal cut-off value for WC, which is an indicator of the degree of visceral fat accumulation, in screening for MAFLD was 102.25 cm (sensitivity 67%, specificity 61%) in males and 101.45 cm (sensitivity 77%, specificity 56%) in females, which was higher than common threshold values for obesity. In other Asian countries, WC and WHtR cutoff values for predicting NAFLD were lower than our results [29,30,31].Visceral fat has a strong correlation with fatty liver, and this condition is linked to a high incidence of lifestyle-related diseases such as hypertension, hyperlipidemia, and diabetes [29].

To the best of our knowledge, this is the first study to evaluate the appropriate cutoff points for anthropometric indices to predict MAFLD risk in the Iranian population. The strength of this study is the inclusion of a large number of individuals who have been diagnosed with MAFLD. In addition, we used updated and novel anthropometric indices for the evaluation of optimal cut-off values. There are several limitations of this study that need to be mentioned. First, due to the cross-sectional study design, we were unable to establish any causal relationships. Second, it is important to note that our findings may not be applicable to other ethnicities, thus necessitating further research on diverse ethnic groups.

Conclusion

In conclusion, we found that all eleven anthropometric indices have diagnostic significance for MAFLD. Principally, WWI was found to be the strongest indicator for predicting MAFLD risk among Iranian adults. Additionally, VAI and RFM emerged as significant indicators, particularly when considering their sensitivity, specificity, and Youden’s Index. Few studies have examined the cutoff points of novel anthropometric indicators for predicting MAFLD risk. Identifying specific indicators with cutoff values for different ethnic and racial groups could aid in the early diagnosis of MAFLD and be helpful in preventing or managing its progression.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Abbreviations

MAFLD:

Metabolic associated fatty liver disease

NAFLD:

Non-alcoholic fatty liver disease

ALD:

Alcoholic liver disease

NASH:

Non-alcoholic steatohepatitis

BMI:

Body mass index

WC:

Waist circumference

HC:

Hip circumference

WHR:

Waist-to-hip ratio

WHtR:

Waist-to-height ratio

BAI:

Body adiposity index

VAI:

Visceral adiposity index

WWI:

Weight-adjusted waist index

CI:

Conicity index

BRI:

Body roundness index

RFM:

Relative fat mass

AVI:

Abdominal volume index

CBC:

Complete blood count

SBP:

Systolic blood pressure

DBP:

Diastolic blood pressure

FBG:

Fasting blood glucose

TC:

Total cholesterol

TG:

Triglyceride

LDL-C:

Low-density lipoprotein cholesterol

HDL-C:

High-density lipoprotein cholesterol

MAP:

Mean Arterial Pressure

ANI:

ALD/NAFLD Index

HIS:

Hepatic steatosis index

AIP:

Atherogenic index of plasma

LAP:

Lipid accumulation product

CMI:

Cardiometabolic index

LCI:

Lipoprotein combine index

AI:

Atherogenic index

TyG:

Triglyceride and glucose index

FPG:

Fasting plasma glucose

ALT:

Alanine aminotransferase

AST:

Aspartate aminotransferase

GGT:

Gamma-glutamyl transpeptidase

References

  1. Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–28.

    Article  CAS  PubMed  Google Scholar 

  2. Seo JY, Cho EJ, Kim MJ, et al. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. J Cachexia Sarcopenia Muscle. 2022;13(6):2953–60.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Tsutsumi T, Nakano D, Kawaguchi M, et al. MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men. Diabetol Metab Syndr. 2022;14(1):115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kaya E, Yilmaz Y. Metabolic-associated fatty liver Disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329–38.

    Article  PubMed  Google Scholar 

  5. Drożdż K, Nabrdalik K, Hajzler W et al. Metabolic-Associated fatty liver Disease (MAFLD), diabetes, and Cardiovascular Disease: associations with Fructose Metabolism and Gut Microbiota. Nutrients. 2021;14(1):103.

  6. Duan S, Yang D, Xia H et al. Cardiometabolic index: a new predictor for metabolic associated fatty liver disease in Chinese adults. Front Endocrinol. 2022;13:1004855.

  7. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9.

    Article  PubMed  Google Scholar 

  8. Zhang R, Guan Q, Zhang M, et al. Association between triglyceride-glucose Index and Risk of Metabolic Dysfunction-Associated fatty liver disease: a Cohort Study. Diabetes Metab Syndr Obes. 2022;15:3167-179.

    Book  Google Scholar 

  9. Yilmaz Y, Yilmaz N, Ates F, et al. The prevalence of metabolic-associated fatty liver disease in the Turkish population: a multicenter study. Hepatol Forum. 2021;2(2):37–42.

    PubMed  PubMed Central  Google Scholar 

  10. Liu J, Ayada I, Zhang X, et al. Estimating Global Prevalence of Metabolic Dysfunction-Associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20(3):e573–82.

    Article  PubMed  Google Scholar 

  11. Cai J, Lin C, Lai S, et al. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the western Chinese male population. Lipids Health Dis. 2021;20(1):1–12.

    Article  Google Scholar 

  12. Taheri E, Moslem A, Mousavi-Jarrahi A, et al. Predictors of metabolic-associated fatty liver disease (MAFLD) in adults: a population-based study in northeastern Iran. Gastroenterol Hepatol Bed Bench. 2021;14(Suppl1):S102–11.

    PubMed  PubMed Central  Google Scholar 

  13. Cordeiro A, Ribamar A, Ramalho A. Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19. Clin Res Hepatol Gastroenterol. 2022;46(3):101807.

    Article  CAS  PubMed  Google Scholar 

  14. Abulmeaty MM, Almajwal AM, Almadani NK, et al. Anthropometric and central obesity indices as predictors of long-term cardiometabolic risk among Saudi young and middle-aged men and women. Saudi Med J. 2017;38(4):372–80.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lajeunesse-Trempe F, Dufour R, du Souich P, et al. Anthropometric measures and their association with risk factors for cardio-metabolic diseases in Kenyan adults. Ann Hum Biol. 2018;45(6–8):486–95.

    Article  CAS  PubMed  Google Scholar 

  16. El Hadi H, Di Vincenzo A, Vettor R et al. Cardio-metabolic disorders in non-alcoholic fatty liver disease. Int J Mol Sci. 2019;20(9):2215.

  17. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32(1):22–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kim D, Konyn P, Sandhu KK, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284–91.

    Article  CAS  PubMed  Google Scholar 

  19. Cheraghian B, Hashemi S, Hosseini J. Cohort profile: the Hoveyzeh Cohort Study (HCS): a prospective population-based study on non-communicable diseases in an arab community of Southwest Iran. Med J Islam Repub Iran. 2020;34:141.

    PubMed  PubMed Central  Google Scholar 

  20. Kani HT, Demirtas CO, Keklikkiran C, et al. Evaluation of the impact of metabolic syndrome on Fibrosis in Metabolic Dysfunction-Associated fatty liver disease. Turk J Gastroenterol. 2021;32(8):661–6.

    Article  PubMed  Google Scholar 

  21. Shen Y, Wu Y, Fu M. al. Association between weight-adjusted-waist index with hepatic steatosis and liver fibrosis: a nationally representative cross-sectional study from NHANES 2017 to 2020. Front Endocrinol. 2023;14:1159055.

  22. Tao J, Zhang Y, Tan C, et al. Associations between weight-adjusted waist index and fractures: a population-based study. J Orthop Surg Res. 2023;18(1):290.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Liu J, Duan S, Wang C, et al. Optimum non-invasive predictive indicators for metabolic dysfunction-associated fatty liver disease and its subgroups in the Chinese population: a retrospective case-control study. Front Endocrinol (Lausanne). 2022;13:1035418.

    Article  PubMed  Google Scholar 

  24. Yang Z, Yu B, Wang Z, et al. Comparison of the prognostic value of a comprehensive set of predictors in identifying risk of metabolic-associated fatty liver disease among employed adults. BMC Public Health. 2023;23(1):584.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Okamura T, Hashimoto Y, Hamaguchi M, et al. The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: a population-based longitudinal study. Clin Res Hepatol Gastroenterol. 2020;44(3):375–83.

    Article  PubMed  Google Scholar 

  26. Ismaiel A, Jaaouani A, Leucuta DC et al. The visceral Adiposity Index in non-alcoholic fatty liver disease and liver fibrosis-systematic review and Meta-analysis. Biomedicines. 2021;9(12):1890.

  27. Woolcott OO, Bergman RN. Relative fat mass (RFM) as a new estimator of whole-body fat percentage a cross-sectional study in American adult individuals. Sci Rep. 2018;8(1):10980.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Machado MV, Policarpo S, Coutinho J, et al. What is the role of the New Index relative Fat Mass (RFM) in the Assessment of nonalcoholic fatty liver Disease (NAFLD)? Obesity surgery. 2020;30(2):560–8.

    Article  PubMed  Google Scholar 

  29. Abe N, Honda S, Jahng D. Evaluation of Waist circumference cut-off values as a marker for fatty liver among Japanese workers. Saf Health Work. 2012;3(4):287–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lee JH, Jeon S, Lee HS et al. Cutoff points of Waist circumference for Predicting Incident non-alcoholic fatty liver disease in Middle-aged and older Korean adults. Nutrients. 2022;14(14):2994.

  31. Yoo HJ, Park MS, Lee CH, et al. Cutoff points of abdominal obesity indices in screening for non-alcoholic fatty liver disease in asians. Liver Int. 2010;30(8):1189–96.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the Editors and reviewers for their constructive and useful comments, which helped improve the quality of this manuscript.

Funding

Not applicable.

Author information

Authors and Affiliations

Authors

Contributions

The authors confirm their contribution to the paper as follows: study conception and design: S.A.H. and M.A. and N.H.; data collection: S.S.; analysis and interpretation of results: H.B. and L.A.; draft manuscript preparation: L.A. and S.A.H. and M.A. and N.H. All authors reviewed the results and approved the final version of the manuscript.

Corresponding author

Correspondence to Ladan Aghakhani.

Ethics declarations

Ethics approval and consent to participate

The study protocol was in accordance with the Helsinki Declarations and approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Science (IR.AJUMS.REC.1400.601).All subjects gave informed consent before entering the study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hosseini, S.A., Alipour, M., Sarvandian, S. et al. Assessment of the appropriate cutoff points for anthropometric indices and their relationship with cardio-metabolic indices to predict the risk of metabolic associated fatty liver disease. BMC Endocr Disord 24, 79 (2024). https://doi.org/10.1186/s12902-024-01615-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12902-024-01615-3

Keywords